Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
about
Risk of Shingles in Adults with Primary Sjogren's Syndrome and Treatments: A Nationwide Population-Based Cohort StudyRisk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritisNon-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Current status and future prospects for biologic treatments of psoriasis.Rheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: perioperative outcomes.Mind and body: how the health of the body impacts on neuropsychiatry.Diagnosis and management of infectious complications of childhood rheumatic diseases.Evidence for a dysregulated immune system in the etiology of psychiatric disorders.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Etanercept: a review of its use in autoimmune inflammatory diseases.Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study.Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.Serious infections among a large cohort of subjects with systemically treated psoriasis.History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis.The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.Immune-based strategies for mood disorders: facts and challenges.[Systemic treatments for psoriasis and psoriatic arthritis].
P2860
Q28547474-92D489ED-178D-4461-B94D-1A1D6A86B459Q30240183-B432C63A-1BF2-46C8-AAD4-8E9EF56F7055Q30245503-C097118B-493D-4AF1-BCE0-913442A258E1Q30725001-2B3902A2-AA84-4499-9D5B-528CCAA1E177Q33778719-17749126-BCB6-49A0-B632-AE5D2CA31B45Q33841390-4188A7A2-0617-4396-945C-0BB6D3081D62Q34756501-8AC2F56B-DDC5-4F43-AD8D-875E822F2D3FQ35636624-7DF05399-41AD-4ED5-953A-EFB205B98264Q35705082-0B8EE4F7-480F-4186-A02A-6B22B8FC005AQ36057909-E68D45ED-824A-42A8-8DBA-462EE57337E8Q37201007-26D96B5D-ADDC-4FE2-A834-C4B192D9F4CEQ37399776-EE8152BD-62B4-4186-8F2A-DE4976D27515Q38084889-77E6C034-D368-4B19-B2E8-30550B75F5EDQ38104284-9548F0F3-E692-4C36-BA98-1CB20DB8326CQ38192553-2B865FDA-CF3F-4A86-8F4F-2A7EE170C6EEQ38207759-585E6FC5-2DC7-451B-AEB9-A8772AF95CEEQ38230740-D270D013-6575-427B-AF3C-ACC5C027EFE7Q38245616-8A360487-1FB6-4E79-80B8-CC5F0F4C32BEQ38864249-EA4E8339-A4C8-4BD0-91CE-2F00DAAB08E0Q40081220-04EC7543-494D-46EC-8F01-5AC247359E4BQ40345791-CA58FEF6-1DCE-4F0C-BA24-6B2D8D98CC9CQ40598586-23E0DDF2-A1E0-440B-B762-77A3CB7C9865Q41362251-A45A5701-A70B-4BC2-A912-8DEFCF9D7D9EQ44815260-582AF4AC-BFD1-4EC8-94A5-116155EC4423Q46339522-933A1230-5596-4953-9D17-B23ABE795995Q46731189-0E3D4F74-AA26-4486-A916-B0B85F52FDA7Q46826040-E7D388FA-4E2B-43E0-AF70-A7151B1EE5C6Q47127624-A3497BE7-B61E-4D74-B5C6-4A8DF4B4DC8EQ47380976-58138310-D32C-4445-A69A-21EC17D56BD1Q47625115-F9768A13-A031-4F88-B5C7-2C83D2B160E6Q47655158-C1DCAEF5-359A-4D0F-8C9F-CEB146BDD1E6Q47694934-2D004880-DB0B-46E2-92C1-BEC47966B702Q52851716-90D6A55F-8CF8-483E-80BF-ABFE4F31CFDA
P2860
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@en
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@nl
type
label
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@en
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@nl
prefLabel
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@en
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@nl
P2093
P1476
Difference in the risk of seri ...... s Monitoring (DREAM) registry.
@en
P2093
A Hartkamp
Jaap Fransen
Marcel Flendrie
Mart A F J van de Laar
Piet L C M van Riel
Sanne A A van Dartel
Wietske Kievit
P304
P356
10.1136/ANNRHEUMDIS-2012-201338
P407
P577
2012-08-11T00:00:00Z